CERS cerus.com: Company Value to Revenue

Official company branding of Cerus (CERS)

The current EV/Sales value demonstrates that the asset is overheated, while the 1775.26 metric indicates a high risk of write-down. Optimized consumables logistics for Cerus Corporation (CERS) eliminate supply disruptions. Leadership in pathogen reduction via INTERCEPT establishes the company as a global safety standard. The production of blood inactivation systems guarantees steady sales to hospitals, minimizing medical risks.

cerus.com (CERS): Enterprise Value-to-Revenue Ratio from 11/23/2025 to 11/20/2026

CERS (Cerus Inc): analytical breakdowns and indicator data

- current quotes and average value forecast:
- company stock capitalization data:
- cash balance and cash flow data:
Fundamental company valuation:Cerus Corporation
Manufactured products of Cerus Corp

The EV/Sales ratio determines the value of a business, including debt and excluding cash, relative to annual revenue. This metric measures the market valuation of one dollar of revenue, neutralizing the impact of capital structure. By analyzing EV/Sales trends, an investor can identify abnormal consolidation prior to volatility spikes. For Cerus Corporation (CERS), this reflects the dependence of capitalization on the adoption rates of blood purification systems. The expansion of technology authorizations directly adjusts the company's fundamental value.

Competitor analysis for Cerus Corporation

ISRG - EV/Sales Multiple|DHR: EV/Sales Multiple|Enterprise Value-to-Revenue Multiple BD (BDX)|Enterprise Value-to-Revenue Ratio STERIS plc|Company Value to Revenue Ratio WST (West Pharmaceutical Services)|Company Value to Revenue BAX (Baxter Corp)|Masimo - Company Value to Revenue Ratio|Stevanato Group S.p.A. - Company Value to Revenue|Total Company Value-to-Revenue Ratio Teleflex Inc (TFX)|MMSI - Enterprise Value-to-Revenue Ratio|Total Company Value-to-Revenue Ratio Envista Holdings Corp NVST|ICUI: EV/Sales Multiple|Company Value to Revenue Ratio XRAY|LMAT (LeMaitre Corp) - EV/Sales Multiple|ATRC (AtriCure Inc) - Enterprise Value-to-Revenue Coefficient|EV/Sales Multiple STAA|NAGE (ChromaDex Corp) - Business Value to Revenue|ZimVie Inc. - Company Value to Revenue|Total Company Value-to-Revenue Ratio angiodynamics.com (ANGO)|teknova.com - EV/Sales Multiple|Enterprise Value-to-Sales Ratio Monogram Technologies Inc. (MGRM)|Sharps Technology, Inc. (STSS) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Multiple InfuSystem Inc (INFU)|UTMD (Utah Medical Products Inc.) - EV/Sales Multiple|Enterprise Value-to-Revenue Multiple KORU Medical Systems KRMD|Enterprise Value-to-Revenue Ratio Nyxoah SA (NYXH)|Enterprise Value-to-Revenue Coefficient MBOT|EV/Sales Multiple PDEX (Pro-Dex Inc.)|Enterprise Value-to-Revenue Coefficient ZTEK (Zentek Limited)|elutia.com - EV/Sales Multiple|Business Value to Revenue MLSS (milestonescientific.com)|NXGL (NEXGEL Inc.) - Company Value to Revenue|Retractable Technologies - Business Value to Revenue|Enterprise Value-to-Revenue Ratio harvardbioscience.com|Femasys Corp (FEMY) - Total Company Value-to-Revenue Ratio|EV/Sales Multiple MHUA|Predictive Oncology Inc. - Company Value to Revenue Ratio|EV/Sales Multiple CJMB (Callan JMB Inc)|EV/Sales Multiple Atrion Corp ATRI|NeuroMetrix Corporation - EV/Sales Multiple